China's HemaCell has received Chinese regulatory approval to begin clinical trials for the world's first allogeneic megakaryocyte cell therapy, targeting chemotherapy-induced thrombocytopaenia. The off-the-shelf injection offers potential advantages over current platelet-boosting drugs and transfusions through sustained platelet production without genetic editing. This marks HemaCell's second clinical approval following Investigational New Drug (IND) clearance in the US for its autologous megakaryocyte therapy, positioning the company as a leader in artificial haematopoiesis.

Founded in 2021, HemaCell specialises in regenerating blood and immune cells through stem cell reprogramming and differentiation technologies. The allogeneic approach promises lower costs and broader accessibility for thrombocytopaenia affecting millions annually. The company aims to achieve commercial approval within two years, potentially capturing a share of the global USD 10 billion platelet-boosting market while advancing China's leadership in cellular therapies for blood disorders.

PharmCube's NextBiopharm® database shows that HemaCell competes with 20 other companies developing 17 chemotherapy-induced thrombocytopaenia therapies. Click here to request a free trial for NextBiopharm®.